166 related articles for article (PubMed ID: 12180841)
1. Activation of complement pathways in xenotransplantation: an in vitro study.
Walpen AJ; Mohacsi P; Frey C; Roos A; Daha MR; Rieben R
Transpl Immunol; 2002 May; 9(2-4):271-80. PubMed ID: 12180841
[TBL] [Abstract][Full Text] [Related]
2. Human alternative complement pathway-mediated lysis of rabbit erythrocytes is enhanced by natural anti-Galalpha1-3Gal antibodies.
Tomlinson S; Nussenzweig V
J Immunol; 1997 Dec; 159(11):5606-9. PubMed ID: 9548503
[TBL] [Abstract][Full Text] [Related]
3. Mouse-to-rabbit xenotransplantation: a new small animal model of hyperacute rejection mediated by the classical complement pathway.
Kerr SR; Dalmasso AP; Apasova EV; Chen SS; Kirschfink M; Matas AJ
Transplantation; 1999 Feb; 67(3):360-5. PubMed ID: 10030279
[TBL] [Abstract][Full Text] [Related]
4. Quantitation and characterization of anti-Galalpha1-3Gal antibodies in sera of 200 healthy persons.
Buonomano R; Tinguely C; Rieben R; Mohacsi PJ; Nydegger UE
Xenotransplantation; 1999 Aug; 6(3):173-80. PubMed ID: 10503783
[TBL] [Abstract][Full Text] [Related]
5. Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gal alpha1,3Gal epitope.
Liu J; Qian Y; Holgersson J
Transplantation; 1997 Jun; 63(11):1673-82. PubMed ID: 9197365
[TBL] [Abstract][Full Text] [Related]
6. The role of natural anti-Gal alpha 1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants.
Lin SS; Kooyman DL; Daniels LJ; Daggett CW; Parker W; Lawson JH; Hoopes CW; Gullotto C; Li L; Birch P; Davis RD; Diamond LE; Logan JS; Platt JL
Transpl Immunol; 1997 Sep; 5(3):212-8. PubMed ID: 9402688
[TBL] [Abstract][Full Text] [Related]
7. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation.
Palmetshofer A; Galili U; Dalmasso AP; Robson SC; Bach FH
Transplantation; 1998 Apr; 65(7):971-8. PubMed ID: 9565103
[TBL] [Abstract][Full Text] [Related]
8. Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry.
Díaz-Román TM; Mañez R; López-Pelaez E; Centeno A; Moscoso I; Pértegaz S; Doménech N
Transpl Immunol; 2006 Aug; 16(2):125-30. PubMed ID: 16860716
[TBL] [Abstract][Full Text] [Related]
9. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients.
Dalmasso AP; Vercellotti GM; Fischel RJ; Bolman RM; Bach FH; Platt JL
Am J Pathol; 1992 May; 140(5):1157-66. PubMed ID: 1580328
[TBL] [Abstract][Full Text] [Related]
11. A murine model of antibody-mediated hyperacute rejection by galactose-alpha(1,3)galactose antibodies in Gal o/o mice.
McKenzie IF; Li YQ; Patton K; Thall AD; Sandrin MS
Transplantation; 1998 Sep; 66(6):754-63. PubMed ID: 9771839
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
Loveland BE; Milland J; Kyriakou P; Thorley BR; Christiansen D; Lanteri MB; Regensburg M; Duffield M; French AJ; Williams L; Baker L; Brandon MR; Xing PX; Kahn D; McKenzie IF
Xenotransplantation; 2004 Mar; 11(2):171-83. PubMed ID: 14962279
[TBL] [Abstract][Full Text] [Related]
13. Differences between synthetic oligosaccharide immunoabsorbents in depletion capacity for xenoreactive anti-Galalpha1-3Gal antibodies from human serum.
Gerber B; Tinguely C; Bovin NV; Rieben R; Nydegger UE
Xenotransplantation; 2001 May; 8(2):106-14. PubMed ID: 11328581
[TBL] [Abstract][Full Text] [Related]
14. Xenotransplantation: in vitro analysis of synthetic alpha-galactosyl inhibitors of human anti-Galalpha1-->3Gal IgM and IgG antibodies.
Rieben R; Bovin NV; Korchagina EY; Oriol R; Nifant'ev NE; Tsvetkov DE; Daha MR; Mohacsi PJ; Joziasse DH
Glycobiology; 2000 Feb; 10(2):141-8. PubMed ID: 10642605
[TBL] [Abstract][Full Text] [Related]
15. Both IgG and IgM anti-pig antibodies induce complement activation and cytotoxicity.
Roos A; Essers M; van Gijlswijk-Janssen D; Bovin NV; Daha MR
Xenotransplantation; 2001 Feb; 8(1):3-14. PubMed ID: 11208186
[TBL] [Abstract][Full Text] [Related]
16. The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts.
Lam TT; Hausen B; Hook L; Lau M; Higgins J; Christians U; Jacobsen W; Baluom M; Duthaler R; Katopodis A; Chavez G; Cozzi E; Harrison R; Schuurman HJ; Borie D; Morris RE
Xenotransplantation; 2005 Jan; 12(1):20-9. PubMed ID: 15598270
[TBL] [Abstract][Full Text] [Related]
17. Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation.
Saethre M; Lea T; Borgen MS; Fiane AE; Michaelsen TE; Thorsby E; Haraldsen G; Mollnes TE
Xenotransplantation; 2006 May; 13(3):215-23. PubMed ID: 16756564
[TBL] [Abstract][Full Text] [Related]
18. Differences in carbohydrate specificities and complement-activating capacity of guinea pig and human antibodies to neuraminidase-treated autologous erythrocytes.
Lambré CR; Pilatte Y; Le Maho S; Blanc C
Mol Immunol; 1985 Sep; 22(9):1123-9. PubMed ID: 2415814
[TBL] [Abstract][Full Text] [Related]
19. Failure to deplete anti-Galalpha1-3Gal antibodies after pig-to-baboon organ xenotransplantation by immunoaffinity columns containing multiple Galalpha1-3Gal oligosaccharides.
Mañez R; Domenech N; Centeno A; Lopez-Pelaez E; Crespo F; Juffe A; Duthaler RO; Katopodis AG
Xenotransplantation; 2004 Sep; 11(5):408-15. PubMed ID: 15303977
[TBL] [Abstract][Full Text] [Related]
20. Production of human monoclonal antibodies against Galalpha(1-3)Gal.
Wittig O; Taylor P; Montaño R; Alonso J; Romano E
Xenotransplantation; 2002 May; 9(3):164-8. PubMed ID: 11983014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
